Aytu Bioscience Inc., of Englewood, Colo., said it received subscriptions of approximately $11.5 million in a private placement of equity units. The issued class A units consist of one share of common stock and a warrant to purchase 1.5 shares of common stock at $0.15 per unit; class B units consist of one share of series A preferred stock and warrants to purchase 1.5 shares of common stock for each share of common stock into which the series A preferred stock is convertible and were sold at $1,000 per unit to those who, together with their affiliates and certain related parties, would beneficially own more than 9.99 percent of the company's outstanding common stock following the offering. The exercise price of the warrants is $0.18 per share, subject to adjustment. Proceeds are expected to be used for sales and marketing expenses to further advance the commercialization of Natesto (testosterone), a nasal gel approved as a replacement therapy for men diagnosed with hypogonadism, and for working capital and general corporate purposes.

Mabvax Therapeutics Holdings Inc., of San Diego, said it entered securities purchase agreements with investors to sell about $1.3 million shares of series J convertible preferred stock, representing approximately 2,386.36 shares at $550 each. The preferred stock is convertible into 2.38 million shares of the company's common stock, based on a fixed conversion price of $0.55 per share and a stated value of $550 per share. The company intends to use the net proceeds from this offering for working capital and general corporate purposes.

Myokardia Inc., of South San Francisco, a biopharma company focused on a precision medicine approach to treat cardiovascular diseases, closed its previously announced underwritten public offering of 4.025 million shares of common stock, at the public offering price of $35.50 per share, which included 525,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. Myokardia estimates net proceeds from the offering to be approximately $133.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. J.P. Morgan Securities LLC and Cowen and Co. LLC acted as joint book-running managers for the offering. BMO Capital Markets Corp. also acted as a bookrunner for the offering. Wedbush Securities Inc. acted as co-manager for the offering. Myokardia's most advanced product candidate is mavacamten (formerly MYK-461), an oral, allosteric modulator of cardiac myosin that reduced hypercontractility in phase I studies of hypertrophic cardiomyopathy patients.

Zealand Pharma A/S, of Copenhagen, said it registered a capital increase of 4.37 million new shares and completed its initial public offering of American depositary shares (ADSs) on the Nasdaq Global Select Market as "ZEAL." The company has granted Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters, an option to purchase up to an additional 656,250 shares to be delivered in the form of ADSs to cover any overallotments.